M1FG
MCRB icon

Mach-1 Financial Group’s Seres Therapeutics MCRB Stock Holding History

Mach-1 Financial Group’s Portfolio MCRB Stock Details MCRB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-4,748
Closed -$455K – 241
2023
Q2 		$455K Buy
+4,748
New +$517K 0.13% 158

Other funds holding MCRB

FP
Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
EP
Eversept Partners New York $1.9B AUM 121.13% 1-Year Est. Return

Mach-1 Financial Group's MCRB Position: Q3 2023 in Review

Mach-1 Financial Group sold out of Seres Therapeutics (MCRB) in Q3 2023, closing a stake of 4,748 shares — an estimated $455K sold.

Mach-1 Financial Group first reported a position in MCRB in Q2 2023 and held it in 1 quarter. The position peaked at $455K in Q2 2023. 134 funds tracked by Wall St. Rank hold MCRB as of Q3 2023.

  • Mach-1 Financial Group reported no remaining Seres Therapeutics position as of Q3 2023 after selling out during the quarter.
  • Mach-1 Financial Group sold 4,748 Seres Therapeutics shares in Q3 2023, an estimated $455K.
  • Mach-1 Financial Group first reported a position in Seres Therapeutics in Q2 2023 and held it in 1 quarter.
  • Mach-1 Financial Group's Seres Therapeutics position peaked at $455K in Q2 2023.
  • 134 funds tracked by Wall St. Rank held Seres Therapeutics as of Q3 2023.

Based on Mach-1 Financial Group's 13F filing for Q3 2023, filed 17 Oct 2023.